Ask AI
ProCE Banner Activity

Evolving Targeted Therapies for Relapsed/Refractory DLBCL

Clinical Thought

The treatment landscape for patients with DLCBL is rapidly evolving with several targeted therapies in the clinical pipeline. In this commentary, experts address key questions about the current role of gemcitabine plus oxaliplatin in relapsed/refractory DLBCL, the curative potential of CAR T-cell therapies vs bispecific antibodies, and the selection and sequencing of targeted therapies following progression on CAR T-cell therapy in the management of patients with relapsed/refractory DLBCL.

Released: August 06, 2026

Share

Provided by

Provided by Clinical Care Options, LLC dba Decera Clinical Education.

ProCE Banner

Supporters

This activity is supported by an educational grant from AstraZeneca.

AstraZeneca

Target Audience

This program is intended for hematologists, oncologists, and other healthcare professionals who care for patients with DLBCL.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Educate colleagues and patients on the mechanisms of action and rationales for using novel targeted therapies in DLBCL

  • Evaluate the potential clinical application of emerging evidence for novel targeted therapies in DLBCL

  • Recommend the optimal targeted treatment for each patient with DLBCL, considering subtype, comorbidities, expert recommendations, and available evidence

  • Identify patients with DLBCL who are eligible for clinical trials evaluating novel targeted therapies

Financial Disclosures

Primary Author

Elizabeth Budde, MD, PhD: consultant/advisor/speaker: AstraZeneca, Bristol Myers Squibb, Crispr, Genentech/Roche; researcher: AstraZeneca, Merck.

Gilles Salles, MD, PhD: consultant/advisor/speaker: AbbVie, ADC Therapeutics, BeOne, Bristol Myers Squibb, Daiichi Sankyo, Genentech/Roche, Genmab, GSK, Incyte, Ipsen, Janssen, Kite/Gilead, Lilly, Merck, Novartis; researcher (paid to institution): AbbVie, Daiichi Sankyo, Genentech, Genmab, Ipsen, Janssen.

Pier Luigi Zinzani, MD, PhD: consultant/advisor/speaker: AbbVie, AstraZeneca, BeOne, Bristol Myers Squibb, Daichii Sankyo, Incyte, Janssen, Kite, Kyowa Kirin, Merck Sharp & Dohme, Novartis, Nurix, Roche, Sobi, Takeda.